The advent of BCMA-directed therapy fills a significant gap in the treatment of relapsed/refractory multiple myeloma. As the field rapidly evolves, clinicians are challenged to navigate an increasingly complex therapeutic landscape. In this clinically relevant, high-level activity, Dr. Sundar Jagganath, Dr. María-Victoria Mateos, and Dr. James Hoffman provide privileged insights into optimal selection and integration of BCMA-directed therapies, particularly bispecific antibodies, to maximize patient outcomes.
Upon successful completion of this educational activity, participants should be better able to:
Chair, Multiple Myeloma
Professor, Medicine
Icahn School of Medicine at Mount Sinai
Director, Multiple Myeloma Center of Excellence
Tisch Cancer Center Institute
Editor-in-Chief, Clinical Lymphoma, Myeloma & Leukemia
Mount Sinai Hospital
New York, NY
Associate Professor, Clinical Medicine
Division of Myeloma (Hematology)
Sylvester Comprehensive Cancer Center (SCCC)
University of Miami
Miami, FL
Associate Professor, Hematology
Director, Myeloma Program
University Hospital of Salamanca
Salamanca, Spain
Featured RMEI CE Activities
Stay up to date with the latest RMEI CE Activities and receive Exclusive Medical Education Resources
